每经AI快讯，2月10日，港股CRO概念股涨幅居前，截至发稿，维亚生物(01873.HK)涨6.14%，报2.42港 元；药明生物(02269.HK)涨6.01%，报40.54港元；泰格医药(03347.HK)涨4.65%，报56.3港元；药明康德 (02359.HK)涨4.31%，报121港元。 ...

Group 1 - CRO concept stocks have shown significant gains, with Weiya Bio rising by 6.14% to HKD 2.42, WuXi Biologics increasing by 6.01% to HKD 40.54, Tigermed up by 4.65% to HKD 56.3, and WuXi AppTec rising by 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's net profit is projected to grow by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that the CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend as innovative drug development heats up [1]

消息面上，2025年药明康德净利润预计同比增加103%，泰格医药同比增加105-204%。全球生物医药投 融资数据在2025年开始回暖，全球和中国2025年同比增速分别为2.7%和6.4%，其中创新药研发火热， 2025年BD金额为1357亿美元，同比增长143%。 国泰海通证券发布研报称，随着融资与BD回款回升，药企重新加大临床试验投入，对临床CRO、SMO 及注册服务的外包需求同步恢复，为行业景气度回升提供直接资金来源与项目基础。德邦证券认为， CXO和科研上游主要服务于创新药的研发和后期生产，随着创新药研发火热，预计两个板块的业绩将 保持良好的趋势。 智通财经APP获悉，CRO概念股涨幅居前，截至发稿，维亚生物(01873)涨6.14%，报2.42港元；药明生 物(02269)涨6.01%，报40.54港元；泰格医药(03347)涨4.65%，报56.3港元；药明康德(02359)涨4.31%， 报121港元。 ...

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a strong rally on February 10, with several companies seeing significant stock price increases [1] - Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rose by over 3% [1] - Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) each saw their stock prices increase by more than 2.5% [1]

Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 维亚生物科技控股集团 (「本公司」) (於開曼群島註冊成立的獲豁免有限公司) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01873 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 4,000,000,000 | | USD | 0.000025 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 4,000,000,000 | USD | 0.000025 | USD | | 100, ...

Core Viewpoint - Via Biotechnology (01873) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., received a response from the Taizhou Ecological Environment Bureau regarding the environmental impact report for the production of several peptides and other small molecule drug intermediates [1] Group 1 - The response approved Langhua Pharmaceutical's plan to renovate three existing factories in the Zhejiang Chemical Raw Material Pharmaceutical Base, Linhai Park, to produce high-level intermediates for peptides and other small molecule drugs [1] - Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report and comply with the requirements set forth in the response, as well as relevant laws and regulations [1] - The production plan is expected to promote business growth, increase production capacity, and benefit the group [1]

Core Viewpoint - Viatris (01873.HK) announced that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., received a response from the Taizhou Ecological Environment Bureau regarding the environmental impact report for the proposed production of certain peptides and other small molecule drug intermediates [1] Group 1 - The response approved Langhua Pharmaceutical's plan to renovate three existing factories in the chemical raw material drug base in the Linhai area of Zhejiang Province for the production of peptide and other small molecule drug intermediates [1] - Langhua Pharmaceutical intends to implement the production plan outlined in the environmental impact report and manage the project in accordance with the relevant requirements and applicable laws and regulations [1] - The production plan is expected to promote business growth, increase production capacity, and benefit the group [1]

生产计划预期将促进集团业务增长、增加其生产能力及产能，从而使集团获益。公司谨此声明，概无就 有关生产计划对集团盈利作出任何预测或预报。 该回覆批准了朗华制药的方案，即根据环境影响报告书所载的条款及计划在浙江省化学原料药基地临海 园区改造叁个现有厂房，以生产多肽及其它小分子药物的高级中间体。朗华制药拟落实环境影响报告书 所载的生产计划，并遵照该回覆提出的相关要求以及相关法律及法规对项目进行管理，力争在可行情况 下尽快投产。 维亚生物(01873)发布公告，公司全资附属公司浙江朗华制药有限公司最近收到来自台州市生态环境局 的回覆，内容有关公司拟生产若干多肽及其它小分子药物的高级中间体等而发出的朗华制药环境影响报 告书。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的獲豁免有限公司） （股份代號：1873） 自願性公告 朗華製藥的環境影響報告書獲批准 本公告由 維亞生物科技控股集團（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作出。 本 公 司 欣 然 宣 佈，本 公 司 全 資 附 屬 公 司 浙 江 朗 華 製 藥 有 限 公 司（「朗華製藥」）最 近 收 到 來 自 台 州 市 生 態 環 境 局 的 回 覆（「該回覆」），內 容 有 關 本 公 司 擬 生 產 若 干 多 肽 及其它小分子藥物的高級中間體等而發出的朗華製藥環境影響報告書。 該 回 覆 批 准 了 朗 華 製 藥 的 方 案，即 根 據 環 境 影 響 報 告 書 所 載 的 條 款 及 計 劃 在 浙 江 省 化 學 原 料 藥 基 地 臨 海 園 區 改 造 三 個 現 有 廠 房，以 ...